Payment overview · 2025
General Payments
$877.42
43 reported records · 14 companies
Healthcare provider profile · identity verified
Russell N Radoff, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1053398511
Verified facts
What the public records show
CMS Open Payments records show Russell N Radoff, MD received $877.42 in general payments during 2025 across 43 reported records.
Novo Nordisk Inc accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $226.58 | 25.8% | 10 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $115.84 | 13.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $102.40 | 11.7% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.19 | 8.6% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.75 | 8.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.18 | 6.5% | 3 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $48.18 | 5.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.12 | 4.9% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $29.49 | 3.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.41 | 3.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.81 | 2.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.36 | 2.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.44 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.67 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $877.42 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $151.47 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $151.47 | 6 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $115.84 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $86.88 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.19 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.11 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $70.75 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.18 | 3 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.88 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 420 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 69 |
| Trazodone Hcl | Trazodone Hcl | 212 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 46 |
| Lisinopril | Lisinopril | 184 | 52 |
| Losartan Potassium | Losartan Potassium | 170 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 32 |
| Gabapentin | Gabapentin | 136 | 32 |
| Synthroid | Levothyroxine Sodium | 119 | 29 |
| Meloxicam | Meloxicam | 109 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 27 |
| Metformin Hcl | Metformin Hcl | 96 | 28 |
| Ezetimibe | Ezetimibe | 95 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 28 |
| Azithromycin | Azithromycin | 83 | 72 |
| Diazepam | Diazepam | 80 | 18 |
| Lorazepam | Lorazepam | 80 | 15 |
| Celecoxib | Celecoxib | 79 | 32 |
| Jardiance | Empagliflozin | 79 | 16 |
| Alendronate Sodium | Alendronate Sodium | 69 | 24 |
| Eliquis | Apixaban | 68 | 15 |
| Simvastatin | Simvastatin | 68 | 20 |
| Alprazolam | Alprazolam | 67 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 18 |
| Sertraline Hcl | Sertraline Hcl | 54 | 12 |
| Omeprazole | Omeprazole | 53 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 17 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 40 |
| Valsartan | Valsartan | 43 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Methylprednisolone | Methylprednisolone | 38 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 17 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $877.42 · 43 records | Novo Nordisk Inc | CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, EVENITY, GARDASIL 9, GEMTESA, Heplisav-B, INSPIRE, Kerendia, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Tymlos, UNITHROID, Wegovy, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error